Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MB | P02144 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817504 | 0.84 | RORC (0.47) | ALDH1A1LMNARORCSMN1; SMN2POLB | |
| SCHEMBL1816036 | 0.83 | IDO1 (0.39) | ALDH1A1LMNARORCPOLBIDO1 | |
| SCHEMBL1818375 | 0.82 | RORC (0.40) | RORCSMN1; SMN2POLBIDO1KDM4E | |
| SCHEMBL1817314 | 0.82 | HPGD (0.40) | ALDH1A1LMNARORCMEN1KMT2A | |
| SCHEMBL1818124 | 0.81 | GAA (0.50) | ALDH1A1LMNARORCMEN1KMT2A | |
| SCHEMBL31311192 | 0.79 | KMT2A (0.38) | ALDH1A1RORCKMT2APOLBIDO1 | |
| SCHEMBL31311285 | 0.77 | RORC (0.44) | ALDH1A1LMNARORCMEN1KMT2A | |
| SCHEMBL27416264 | 0.77 | RORC (0.45) | ALDH1A1PKMLMNARORCSMN1; SMN2 | |
| SCHEMBL1820066 | 0.75 | ALDH1A1 (0.51) | ALDH1A1PKMLMNAMEN1KMT2A | |
| SCHEMBL25236323 | 0.73 | ALDH1A1 (0.42) | ALDH1A1PKMLMNARORCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Cadrenal Therapeutics, Inc. | 2025-02-27 | — | — | US | disclosed |
| WO-2024264032-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-119013013-A | Compositions and methods of use for treating 12-lipoxygenase (12-LOX) -mediated diseases | 维拉洛斯治疗公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4452251-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023122494-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | ALDH1A1 4190/4885PKM 4195/4885LMNA 3490/4885 |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | ALOX12, LOX, ALOX15 | ALDH1A1 745/4885PKM 1768/4885LMNA 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.